360 High-Risk Vulnerability Immunization Tool V2.0 vs Blue Ridge Networks AppGuard: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Blue Ridge Networks AppGuard: Zero Trust endpoint & server breach prevention via app isolation/containment. built by Blue Ridge Networks. Core capabilities include Application isolation and containment, Breach prevention without detection/signature reliance, Attack surface reduction..

Both serve the Endpoint Protection Platform market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Blue Ridge Networks AppGuard differentiates with Application isolation and containment, Breach prevention without detection/signature reliance, Attack surface reduction.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Blue Ridge Networks AppGuard is developed by Blue Ridge Networks. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Blue Ridge Networks AppGuard serve similar Endpoint Protection Platform use cases: both are Endpoint Protection Platform tools, both cover Windows Security. Review the feature comparison above to determine which fits your requirements.